MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer.

Chuansheng Yang,Hongbo Zhu,Yeru Tan,Renjie Zhu,Xiaoping Wu,Yuehua Li,Cunchuan Wang
DOI: https://doi.org/10.2174/1568009621666210618164300
2021-01-01
Current Cancer Drug Targets
Abstract:Background: The function of MALAT1, a long non-coding RNAs (lncRNA), in HER2positive breast cancer remains largely unexplored. Objectives: This study aimed to investigate the effect of MALAT1 on tumor development in HER2-positive breast cancer. Methods: We detected MALAT1 expression in HER2-positive breast cancer cells and tissues, and analyzed the effects of MALAT1 on cell proliferation in HER2-positive breast cancer cells lines (BT-474 and SKBR3). A mouse xenograft model was established for detecting the function of MALAT1 in HER2-positive breast cancer. Results and Discussion: As a result, MALAT1 was remarkably up-regulated in HER2-positive breast cancer both in cells and tissues. In addition, the silencing of MALAT1 inhibited the proliferation of HER2-positive breast cancer cells bothin vitro and in vivo. Furthermore, knockdown of MALAT1 by shRNA down-regulated DNMT1, DNMT3a, and DNMT3b, while up-regulated BRCA1 and PTEN in HER2-positive breast cancer both in cell lines and mouse xenograft models. Conclusion: In short, MALAT1 might be a potential biomarker and therapeutic target for HER2positive breast cancer therapy.
What problem does this paper attempt to address?